<DOC>
	<DOCNO>NCT01761994</DOCNO>
	<brief_summary>Continuous renal replacement therapy ( CRRT ) consider effective modality renal replacement therapy hemodynamically unstable patient within intensive care unit ( ICU ) except necessity anticoagulation . The severity peculiarity ICU patient often make equivocal use anticoagulation . This prospective randomized control study show difference filter life span adverse event HF1000 ( nafamostat mesilate ) group M100 ( heparin-free ) group .</brief_summary>
	<brief_title>The Effect Nafamostat Mesilate Prolonging Filter Patency With Patients Continuous Renal Replacement Therapy</brief_title>
	<detailed_description />
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Nafamostat</mesh_term>
	<criteria>patient least one hemorrhagic tendency follow condition need CRRT hemodynamically ; 1 . Platelet count &lt; 100,000 2. aPTT &gt; 60 sec 3 . PTINR &gt; 2.0 4. active hemorrhage 5. surgery within 48 hour 6. cerebral hemorrhage within 3 month history major bleed 7. septic shock DIC . pregnancy , breast feeding , possibility pregnancy , allergy nafamostat mesilate , condition physician consider unfit candidate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>nafamostat mesilate</keyword>
	<keyword>heparin</keyword>
	<keyword>continuous renal replacement therapy</keyword>
</DOC>